Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia

Nordling, Jørgen

doi:10.1111/j.1464-410x.2005.05456.x

Cited by 89 publications

(82 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The severity of LUTS was categorized as mild (score < 8), moderate (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) and severe (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). The bother score was categorized as ≤ 3 and > 3 (i.e.…”

Section: Alfmentioning

confidence: 99%

Long‐term efficacy and safety of alfuzosin 10 mg once daily: a 2‐year experience in ‘real‐life’ practice

Elhilali

Emberton

Matzkin³

et al. 2006

BJU International

View full text Add to dashboard Cite

OBJECTIVETo assess the 2-year efficacy and safety of alfuzosin 10 mg once daily, a selective α 1 -adrenoceptor antagonist, in men complaining of lower urinary tract symptoms (LUTS) suggestive of benign prostate hyperplasia (BPH), in 'real life' practice. PATIENTS AND METHODSIn all, 839 European men with LUTS (mean age 67.3 years) were enrolled by general practitioners in a 2-year open-label study with alfuzosin 10 mg once daily. They were asked to complete the International Prostate Symptom Score (IPSS), its appended eighth question (bother score), and the five domains (sexual drive, erection, ejaculation, problem assessment, and overall satisfaction) of the Brief Male Sexual Function Inventory (BSFI). The results were analysed at the endpoint in the intent-to-treat population. RESULTSAt the endpoint the total IPSS improved by 7 points ( − 38.5%) from baseline ( P < 0.001) with 76.9% and 49.7% of men having an improvement of ≥ 3 points and > 6 points, respectively. There were also significant improvements in nocturia ( − 0.9, − 30%; P < 0.001) and bother score ( − 1.8, − 43%; P < 0.001) from baseline. Most patients (56%) perceived symptom relief within the first 2 weeks of treatment. All BSFI domains significantly improved from baseline ( P < 0.05; < 0.001 for overall satisfaction) and these improvements were more marked in men with severe LUTS at baseline. Alfuzosin 10 mg was well tolerated; the most common adverse event related to vasodilatation was dizziness/postural dizziness (3.1%). Ejaculatory disorders were uncommon (0.3%). Changes in blood pressure remained marginal, including in elderly men and those receiving antihypertensive agents. CONCLUSIONSAlfuzosin 10 mg administered for 2 years in real practice is effective in improving LUTS and quality of life, and is well tolerated from a cardiovascular perspective, including in elderly men and those receiving antihypertensive co-medication. Ejaculatory disorders are uncommon. Alfuzosin may even slightly improve various domains of sexual function, such as sexual drive, erection, ejaculation and satisfaction with sexual life. A joint study was conducted by authors from Argentina and Brazil into the use of an adjustable male sling in the treatment of incontinence after prostatectomy. They were encouraged by the early results, feeling that the product they were evaluating might potentially present an alternative to the use of the artificial urinary sphincter in this condition.

show abstract

Section: Alfmentioning

confidence: 99%

Long‐term efficacy and safety of alfuzosin 10 mg once daily: a 2‐year experience in ‘real‐life’ practice

Elhilali

Emberton

Matzkin³

et al. 2006

BJU International

View full text Add to dashboard Cite

show abstract

“…6,7 Although the safety and efficacy of both a 1 -blockers and PDE-5 inhibitors are well established individually and have been prescribed with minimal limitations related to side effects, there are few reports regarding the safety and efficacy of coadministering both types of agents. [8][9][10][11] Moreover, the pharmacotherapy of both PDE-5 inhibitors and a-blockers has the same potential side effects associated with the hemodynamic status and the cardiovascular system, hence it is important that concerns regarding the potential hemodynamic consequences of the simultaneous administration of a 1 -blockers and PDE-5 inhibitors are addressed. When considering the characteristics of aging patients with a high prevalence of comorbidity with other cardiovascular risk factors (for example, hypertension and diabetes mellitus), the possibility of cardiovascular side effects related to the coadministration of these agents is of ethical concern for the physician.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS

Chung

Lee

et al. 2009

Int J Impot Res

View full text Add to dashboard Cite

We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable a-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks.Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, Po0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an a-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.

show abstract

“…was shown to be an effective and well-tolerated treatment for symptomatic BPH in three pivotal, placebo-controlled, clinical trials. [8][9][10][11] In these clinical trials, symptom relief during 12 weeks of treatment with alfuzosin 10 mg q.d. or placebo was first assessed at 4 weeks post-treatment using the International Prostate Symptom Score (IPSS) and measurements of peak urinary flow rate (Q max ).…”

Section: Introductionmentioning

confidence: 99%

Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia

2007

View full text Add to dashboard Cite

We evaluated the effects of extended-release alfuzosin HCl 10 mg once daily (q.d.) on sexual function in men with lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). In a randomized, double-blind, placebo-controlled study of men aged Z50 years, after a 28-day placebo run-in period, patients were randomized to receive alfuzosin 10 mg q.d. or matching placebo for 28 days. The mean change from baseline (day 1) in sexual function on day 29 was assessed using the Danish Prostate Symptom Score Sex (DAN-PSSsex) questionnaire. A total of 372 patients were randomized to receive alfuzosin (n ¼ 186) or placebo (n ¼ 186), with 355 completing the study. At baseline, 64% of the patients reported erectile dysfunction (ED) and 63% reported ejaculatory dysfunction (EjD). For the 320 patients who completed the DAN-PSSsex, alfuzosin treatment was associated with a significant improvement in the mean change from baseline in erectile function on day 29 compared with placebo (P ¼ 0.02). No significant difference was observed between the two treatment groups in the mean change from baseline in ejaculatory function on day 29. For patients with ED at baseline, a marginal improvement in erectile function was demonstrated with alfuzosin treatment (P ¼ 0.09 vs placebo). For patients with EjD at baseline, the mean change from baseline in ejaculatory function with alfuzosin was comparable to that with placebo. Dizziness was the most common adverse event with alfuzosin treatment (5 vs 0% with placebo), with other adverse events reported with comparable frequency in both treatment groups. After 1 month of treatment, alfuzosin 10 mg q.d. significantly improved erectile function in men with lower urinary tract symptoms/ benign prostatic hypertrophy and had no adverse effect on ejaculatory function.

show abstract

Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia

Cited by 89 publications

References 28 publications

Long‐term efficacy and safety of alfuzosin 10 mg once daily: a 2‐year experience in ‘real‐life’ practice

Long‐term efficacy and safety of alfuzosin 10 mg once daily: a 2‐year experience in ‘real‐life’ practice

Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS

Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia

Contact Info

Product

Resources

About